Implementation of the 2018 ESC/ESH Guidelines for the management of hypertension in primary care: the HYPEDIA study

Abstract

The HYPEDIA study aimed at evaluating the implementation of the 2018 European guidelines for treating hypertension in primary care. A nationwide prospective non-interventional cross-sectional study was performed in consecutive untreated or treated hypertensives recruited mainly in primary care in Greece. Participants’ characteristics, office blood pressure (BP) (triplicate automated measurements, Microlife BPA3 PC) and treatment changes were recorded on a cloud platform. A total of 3,122 patients (mean age 64 ± 12.5 [SD] years, 52% males) were assessed by 181 doctors and 3 hospital centers. In 772 untreated hypertensives (25%), drug treatment was initiated in the majority, with monotherapy in 53.4%, two-drug combination in 36.3%, and three drugs in 10.3%. Angiotensin receptor blocker (ARB) monotherapy was initiated in 30%, ARB/calcium channel blocker (CCB) 20%, ARB/thiazide 8%, angiotensin converting enzyme inhibitor (ACEi)-based 19%. Of the combinations used, 97% were in single-pill. Among 977 treated hypertensives aged <65 years, 79% had BP ≥ 130/80 mmHg (systolic and/or diastolic), whereas among 1,373 aged ≥65 years, 66% had BP ≥ 140/80 mmHg. ARBs were used in 69% of treated hypertensives, CCBs 47%, ACEis 19%, diuretics 39%, beta-blockers 19%. Treatment modification was decided in 53% of treated hypertensives aged <65 years with BP ≥ 130/80 mmHg and in 62% of those ≥65 years with BP ≥ 140/80 mmHg. Renin-angiotensin system blocker-based therapy constitutes the basis of antihypertensive drug treatment in most patients in primary care, with wide use of single-pill combinations. In almost half of treated uncontrolled hypertensives, treatment was not intensified, suggesting suboptimal implementation of the guidelines and possible physician inertia.

Blood pressure changes during tenofovir-based antiretroviral therapy among people living with HIV in Lilongwe, Malawi: results from the prospective LighTen Cohort Study

“…Besides patient-related factors such as non-adherence, the reasons for uncontrolled BP are manifold, including irregular supply of antihypertensive drugs with frequent changes in prescriptions (and hence reduced adherence), substandard quality of drugs, shortage of health workers and centers, and poverty in general [ 60 , 61 ]. In addition, physician inertia is a well-known phenomenon in the case of treated, but uncontrolled hypertension [ 62 ]. The same phenomenon has been observed for treating clinical officers and nurses in the present LighTen Study with its low rate (13%) of treatment adjustments in patients with BP ≥ 140/90 mmHg during patient visits.…”

Genetic polymorphism of the Dab2 gene and its association with Type 2 Diabetes Mellitus in the Chinese Uyghur population

“…BMI was obtained by calculating the participant’s weight divided by the square of their height (kg/m 2 ). We defined hypertension as a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg in at least two clinic blood pressure measurements on different days ( Kollias et al, 2022 ). We defined smoking as currently or previously smoking, and drinking was defined as drinking alcohol at least once a week for at least a year ( Xie et al, 2010 ).…”

COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis

“…As guidelines have assessed, renin–angiotensin system blockers (angiotensin-converting enzyme or ACEI/angiotensin II receptor antagonists such as, ARAII) are recommended in the first step of pharmacological treatment. This is supported by the strong evidence of cardiovascular and renal protection with these drug classes [ 11 ]. Therefore, these antihypertensives have a theoretical increase in COVID-19 mortality because of their inducible effect on the expression of angiotensin-converting enzyme II (ACEII), the known functional receptor utilized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [ 12 ].…”